drugset / Trial / NCT02312414

Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype

NCT02312414

Unknown 25 enrolled The Nazareth Hospital, Israel
RandomizedCrossoverOpen-labelTreatment

Summary

Anemia is a common disorder in CKD patients. It is largely attributed to decreased erythropoietin (EPO) production and iron deficiency. Therefore, besides EPO, therapy includes iron replenishment. However, the latter induces oxidative stress. Haptoglobin (Hp) protein is the main line of defense against the oxidative effects of Hemoglobin/Iron. There are 3 genotypes: 1-1, 2-1 and 2-2. Hp 2-2 protein is inferior to Hp 1-1 as antioxidant. So far, there is no evidence whether haptoglobin genotype affects iron-induced oxidative stress in CKD patients. In this proposed study we wished to examine whether Hp genotype influences intravenous iron administration (IVIR)-induced oxidative stress in CKD patients, and its impact on the response of these patients to L-Carnitine therapy.

Timeline

Start
2014-10
Primary completion
2015-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Carnitine Small molecule 20 mg/kg Intravenous

Indications